Join Premier Research at the World Orphan Congress EU for groundbreaking solutions, exclusive insights, and unmatched networking. Elevate your approach to rare diseases – visit our exhibit and be part of the future of orphan drug development!

Join Corinne Blanchet, Executive Director, Program Delivery, Rare Disease, who will be addressing the challenges of diversity in rare disease clinical trials.

Diversity and Equity in Clinical Studies: Impact on Rare Disease

October 23, 2024, 3:10 – 3:40 P.M., Clinical Operations Stream

The FDA’s diversity guidance for clinical trials marks a significant step towards equity in medical research. This presentation will help us to understand its impact on sponsors, patients, and advocacy groups. Sponsors must now adopt inclusive trial designs and recruitment strategies, while patients gain improved access to tailored treatments, fostering trust. Advocacy groups play a pivotal role in raising awareness and engagement among underrepresented communities. In the context of rare disease trials, where identifying patients is exceptionally challenging, striking a balance between inclusivity and sufficient enrollment is crucial. This presentation will explore the potential of FDA diversity guidelines across medical research stakeholders, addressing the nuanced challenges of patient identification and trial participation in rare disease research.